贝利尤单抗治疗系统性红斑狼疮（SLE）：迄今的证据及临床应用价值
Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness.
作者信息
Guerreiro Castro Sara, Isenberg David A
机构信息
Autoimmune Diseases Unit, Internal Medicine 7.2 Dept, Hospital Curry Cabral, Centro Hospitalar Lisboa Central, Lisbon, Portugal.
Centre for Rheumatology, University College London, Room 424, 4th Floor Rayne Building, 5 University Street, London WC1E 6JF, UK.
出版信息
Ther Adv Musculoskelet Dis. 2017 Mar;9(3):75-85. doi: 10.1177/1759720X17690474. Epub 2017 Mar 1.
Abstract
Systemic lupus erythematosus (SLE) is a complex autoimmune rheumatic disease with multiple presentations, whose management presents many challenges. Many disease modifying or immunosuppressive drugs have been used with limited success, especially in patients with more severe disease activity. Belimumab is the first drug to be approved specifically for the treatment of SLE in more than 50 years. By blocking the B-cell activating factor, it interferes in B-cell differentiation and survival. Here we consider the results of the clinical trials that led to its approval, as well as the post-hoc analyses, follow-up studies and the current trials.
摘要
系统性红斑狼疮（SLE）是一种具有多种表现形式的复杂自身免疫性风湿疾病，其治疗面临诸多挑战。许多改善病情或免疫抑制药物的使用效果有限，尤其是在疾病活动较为严重的患者中。贝利尤单抗是50多年来首个被专门批准用于治疗SLE的药物。通过阻断B细胞活化因子，它可干扰B细胞的分化和存活。在此，我们探讨了促成其获批的临床试验结果，以及事后分析、随访研究和当前的试验情况。
相似文献
1
Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness.贝利尤单抗治疗系统性红斑狼疮（SLE）：迄今的证据及临床应用价值
Ther Adv Musculoskelet Dis. 2017 Mar;9(3):75-85. doi: 10.1177/1759720X17690474. Epub 2017 Mar 1.
2
Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.贝利尤单抗治疗系统性红斑狼疮的疗效、药代动力学及药效学特征
Expert Opin Drug Metab Toxicol. 2015;11(10):1635-45. doi: 10.1517/17425255.2015.1077808. Epub 2015 Sep 1.
3
Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.打破系统性红斑狼疮的僵局：贝利尤单抗，一种有前途的新疗法。
Lupus. 2013 Apr;22(4):361-71. doi: 10.1177/0961203312471575.
4
Belimumab for the treatment of systemic lupus erythematosus.贝利尤单抗用于治疗系统性红斑狼疮。
Expert Rev Clin Immunol. 2015 Feb;11(2):195-204. doi: 10.1586/1744666X.2015.996550. Epub 2014 Dec 29.
5
Belimumab: review of use in systemic lupus erythematosus.贝利尤单抗：治疗系统性红斑狼疮的应用评价。
Clin Ther. 2012 May;34(5):1006-22. doi: 10.1016/j.clinthera.2012.02.028. Epub 2012 Mar 30.
6
Belimumab for systemic lupus erythematosus: a practice-based view.贝利尤单抗治疗系统性红斑狼疮：基于实践的观点。
Lupus. 2013 Apr;22(4):372-80. doi: 10.1177/0961203313476154.
7
Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.皮下注射和静脉注射贝利尤单抗治疗系统性红斑狼疮：皮下和静脉给药数据综述。
Expert Rev Clin Immunol. 2017 Oct;13(10):925-938. doi: 10.1080/1744666X.2017.1371592.
8
Belimumab in systemic lupus erythematosus: a perspective review.贝利尤单抗治疗系统性红斑狼疮：一篇综述
Ther Adv Musculoskelet Dis. 2015 Aug;7(4):115-21. doi: 10.1177/1759720X15588514.
9
Update on belimumab for the management of systemic lupus erythematosus.贝利尤单抗治疗系统性红斑狼疮的最新进展
Expert Opin Biol Ther. 2014 Nov;14(11):1701-8. doi: 10.1517/14712598.2014.959924.
10
Belimumab in systemic lupus erythematosus.贝利尤单抗治疗系统性红斑狼疮。
RMD Open. 2015 Mar 3;1(1):e000011. doi: 10.1136/rmdopen-2014-000011. eCollection 2015.
引用本文的文献
1
CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon.自身免疫性疾病中的嵌合抗原受体T细胞疗法：一个充满前景的前沿领域。
Front Immunol. 2025 Aug 12;16:1613878. doi: 10.3389/fimmu.2025.1613878. eCollection 2025.
2
EULAR 2023 Recommendations for the Management of Systemic Lupus Erythematosus: One Step Forward.欧洲抗风湿病联盟（EULAR）2023年系统性红斑狼疮管理建议：向前迈进一步。
Mediterr J Rheumatol. 2024 Mar 31;35(1):63-65. doi: 10.31138/mjr.130124.erm. eCollection 2024 Mar.
3
Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?在自身免疫性疾病中阻断 B 和 T 细胞协作：T 细胞衔接器与 CAR-T 细胞疗法？
Clin Exp Immunol. 2024 Jun 20;217(1):15-30. doi: 10.1093/cei/uxae031.
4
Current Treatment Approach, Emerging Therapies and New Horizons in Systemic Lupus Erythematosus.系统性红斑狼疮的当前治疗方法、新兴疗法及新展望
Life (Basel). 2023 Jul 1;13(7):1496. doi: 10.3390/life13071496.
5
Promising Experimental Treatments for Lupus Nephritis: Key Talking Points and Potential Opportunities.狼疮性肾炎的前景看好的实验性治疗方法：关键要点和潜在机会。
Res Rep Urol. 2023 Jul 10;15:333-353. doi: 10.2147/RRU.S385836. eCollection 2023.
6
Clinical characterization of a cohort of patients treated for systemic lupus erythematosus in Colombia: A retrospective study.对在哥伦比亚接受系统性红斑狼疮治疗的患者队列进行的临床特征描述：一项回顾性研究。
PLoS One. 2023 May 18;18(5):e0285889. doi: 10.1371/journal.pone.0285889. eCollection 2023.
7
Impact of Innovative Treatment Using Biological Drugs for the Modulation of Diffuse Cutaneous Systemic Sclerosis: A Systematic Review.生物药物治疗弥漫性皮肤系统性硬化症的影响：系统评价。
Medicina (Kaunas). 2023 Jan 27;59(2):247. doi: 10.3390/medicina59020247.
8
Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis.系统性硬化症的治疗选择：应对免疫介导性纤维化的现状与未来展望
Biomedicines. 2022 Jan 29;10(2):316. doi: 10.3390/biomedicines10020316.
9
Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis.新型脾酪氨酸激酶抑制剂兰瑞替尼在狼疮性肾炎模型中的作用机制表征
BMC Rheumatol. 2021 Mar 30;5(1):15. doi: 10.1186/s41927-021-00178-3.
10
The safety and efficacy of biologic agents in treatment of systemic lupus erythematosus: A network meta-analysis.生物制剂治疗系统性红斑狼疮的安全性和有效性：一项网状Meta分析。
Pak J Med Sci. 2019 Nov-Dec;35(6):1680-1686. doi: 10.12669/pjms.35.6.771.
本文引用的文献
1
Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials.系统性红斑狼疮患者 52 周累积皮质类固醇剂量：来自 III 期贝利尤单抗试验的汇总分析。
Arthritis Rheumatol. 2016 Sep;68(9):2184-92. doi: 10.1002/art.39682.
2
Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care.贝利尤单抗联合标准治疗方案治疗系统性红斑狼疮患者的长期器官损害累积及安全性
Lupus. 2016 Jun;25(7):699-709. doi: 10.1177/0961203315625119. Epub 2016 Mar 1.
3
Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA.在临床实践环境中接受贝利尤单抗治疗的系统性红斑狼疮患者的应答情况：来自美国 OBSErve 研究的 24 个月结果。
Lupus Sci Med. 2016 Jan 11;3(1):e000118. doi: 10.1136/lupus-2015-000118. eCollection 2016.
4
Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices.贝利尤单抗在学术临床实践中治疗系统性红斑狼疮的安全性和有效性。
J Rheumatol. 2015 Dec;42(12):2288-95. doi: 10.3899/jrheum.150470. Epub 2015 Nov 1.
5
Systemic lupus erythematosus exacerbation following cessation of belimumab treatment.贝利尤单抗治疗停药后系统性红斑狼疮病情加重。
Scand J Rheumatol. 2016;45(2):103-6. doi: 10.3109/03009742.2015.1074277. Epub 2015 Oct 29.
6
Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis.在意大利背景下评估贝利尤单抗治疗系统性红斑狼疮的经济影响：一项成本效益分析。
PLoS One. 2015 Oct 21;10(10):e0140843. doi: 10.1371/journal.pone.0140843. eCollection 2015.
7
[Cost-effectiveness analysis of Belimumab in patients with systemic lupus erythematosus in Spain].[贝利尤单抗在西班牙系统性红斑狼疮患者中的成本效益分析]
Farm Hosp. 2015 May 1;39(3):161-70. doi: 10.7399/fh.2015.39.3.8814.
8
Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials.系统性红斑狼疮反应指数应答的临床、实验室和健康相关生活质量相关性：III 期贝利尤单抗试验的事后分析。
Lupus Sci Med. 2014 Jun 26;1(1):e000031. doi: 10.1136/lupus-2014-000031. eCollection 2014.
9
Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus.贝利尤单抗的卫生技术评估：一种用于治疗系统性红斑狼疮的新型单克隆抗体。
Biomed Res Int. 2014;2014:704207. doi: 10.1155/2014/704207. Epub 2014 Aug 17.
10
Post-marketing experiences with belimumab in the treatment of SLE patients.贝利尤单抗治疗系统性红斑狼疮患者的上市后经验。
Rheum Dis Clin North Am. 2014 Aug;40(3):507-17, viii. doi: 10.1016/j.rdc.2014.04.007. Epub 2014 Jun 3.
Zotero 插件